March 30, 2017 02:00 ET

Angle PLC Announces Potential for Prediction of Metastasis in Prostate Cancer

GUILDFORD, UNITED KINGDOM--(Marketwired - Mar 30, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)


For immediate release 30 March 2017

ANGLE plc ("the Company")


Barts Cancer Institute present new findings at World CDx Europe 2017 conference in London

ANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, is delighted to announce that researchers from the Barts Cancer Institute (BCI), Queen Mary University of London, have presented new results at the World CDx Europe 2017 conference in London of their work with ANGLE's Parsortix system in prostate cancer. The new findings suggest a broader range of potential applications for Parsortix in prostate cancer from early to late disease prognosis.

Metastasis, the spread of cancer to another part of the body, is responsible for over 90% of cancer-related deaths. Consequently, a key issue in the treatment of prostate cancer is to determine whether the cancer has been contained or whether it is continuing to progress to metastasis. In the latter case, the earlier treatment can be deployed the better.

BCI have now completed a pilot study in over 80 patients to evaluate the capability of Parsortix to be used to identify whether prostate cancer patients have progressed to metastasis. The results presented today indicate that the use of Parsortix, in combination with existing assessments, is potentially more effective than existing parameters currently used to predict metastasis in identifying those patients who have progressed to metastasis. 

The gold standard for detecting metastasis is imaging. This cannot be predictive as it is imaging metastatic sites that have already developed. Utilising Parsortix it may be possible to improve the prediction of the likely development of metastasis early and/or to identify the presence of metastasis before it can be seen by imaging technologies. This would benefit patients by allowing early treatment and by reducing harmful exposure to radioactive imaging.

The Parsortix analysis is based on analysis of mesenchymal CTCs, which cannot be undertaken using alternative antibody-based systems or by ctDNA analysis.

Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer Institute, commented:
"Our latest results demonstrate the potential for the Parsortix system to be used to identify patients with metastasis through a simple blood test. This offers the potential for the prediction and/or early detection of metastasis, which would meet a key need in the treatment of prostate cancer, the most common cancer in men."

ANGLE Founder and Chief Executive, Andrew Newland, commented:
"This is another significant milestone in progressing the development of Parsortix for the treatment of prostate cancer. The new results further support the expansion of the potential clinical application to include both early and late stage prostate cancer."

For further information:

ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser), Steve Cox
Russell Kerr (Sales)  
020 7397 8900
WG Partners
David Wilson
Claes Spång
020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert
Kimberly Ha (US)  

020 3727 1000
001 212 850 5612

For Frequently Used Terms, please see the Company's website on

This announcement contains inside information.

Notes for editors

About ANGLE plc 
ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States. 

ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit:

This information is provided by RNS
The company news service from the London Stock Exchange

Contact Information